Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc., has reported significant stock transactions in a recent SEC filing. This activity, which includes both acquisitions and sales of common stock, is noteworthy as it reflects Hohl's active management of his personal stock holdings. Such transactions can provide insights into executive compensation and ownership strategies, particularly within the pharmaceutical industry.
Background
Enliven Therapeutics, Inc. operates within the pharmaceutical preparations sector, classified under the Standard Industrial Classification (SIC) code 2834. The company is based in Burlingame, California, and is publicly traded under the ticker symbol ELVN. Recent filings indicate a consistent pattern of stock transactions by Hohl, showcasing his engagement with the company's equity.
What the Filing Says
In the filing dated October 21, 2026, Hohl disclosed multiple transactions that occurred on October 19, 2026. He acquired 6,018 shares of common stock at a price of $14.85 per share and simultaneously sold 6,018 shares at a weighted average price of $38.4755. Following these transactions, Hohl's total ownership of the company's stock stands at 38,000 shares.
Impact
This activity may affect various stakeholders, including investors and analysts monitoring executive actions. Hohl's transactions may signal confidence in the company's future prospects, potentially influencing investor sentiment. Additionally, the pharmaceutical preparations industry may observe similar behaviors as executives manage their compensation and investment strategies.
What's Next
The filing does not say what happens next.